PXD032359

PXD032359 is an original dataset announced via ProteomeXchange.

Title	Circulating SOD2 is a Response Biomarker for Neoadjuvant Therapy in Breast Cancer
Description	There is a great need of non-invasive tools that inform of an early molecular response to cancer therapeutic treatment. Here, we have tested the hypothesis that proteolytically resistant proteins could be candidate circulating tumor biomarkers for cancer therapy. Proteins resistant to proteolysis are drastically under-sampled by current proteomic workflows. These proteins could be reliable sensors for the response to therapy since they are likely to stay longer in circulation. We selected Manganese superoxide dismutase (SOD2), a mitochondrial redox enzyme, from a screening of proteolytic resistant proteins in breast cancer (BC). First, we confirmed the robustness of SOD2 and determined that its proteolytic resistance is mediated by its quaternary protein structure. We also proved that the release of SOD2 upon chemotherapy treatment correlates with cell death in BC cells. Then, after confirming that SOD2 is very stable in human serum, we sought to measure its circulating levels in a cohort of BC patients undergoing neoadjuvant therapy. The results showed that circulating levels of SOD2 increased when patients respond to the treatment according to the tumor shrinkage during neoadjuvant chemotherapy. Therefore, the measurement of SOD2 levels in plasma could improve the non-invasive monitoring of the therapeutic treatment in breast cancer patients. The identification of circulating biomarkers linked to the tumor cell death induced by treatment could be a useful for monitoring the action of the large number of cancer drugs currently used in the clinic. We envision that our approach could help uncover candidate tumor biomarkers to measure a tumor’s response to cancer therapy in real time by sampling the tumor throughout the course of treatment.
HostingRepository	PRIDE
AnnounceDate	2023-11-14
AnnouncementXML	Submission_2023-11-14_07:57:32.924.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Francesc Canals
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	No PTMs are included in the dataset
Instrument	LTQ Orbitrap Velos

Revision	Datetime	Status	ChangeLog Entry
0	2022-03-17 04:22:31	ID requested
1	2023-01-09 07:52:34	announced
⏵ 2	2023-11-14 07:57:35	announced	2023-11-14: Updated project metadata.

Juliachs M, Pujals M, Bellio C, Meo-Evoli N, Duran JM, Zamora E, Par, é, s M, Su, ñ, ol A, M, é, ndez O, S, á, nchez-Pla A, Canals F, Saura C, Villanueva J, Circulating SOD2 Is a Candidate Response Biomarker for Neoadjuvant Therapy in Breast Cancer. Cancers (Basel), 14(16):(2022) [pubmed]

submitter keyword: proteolysis-resistant proteins,SOD2, biomarker

Josep Villanueva
contact affiliation	Vall d'Hebron Institute of Oncology (VHIO)
contact email	jvillanueva@vhio.net
lab head
Francesc Canals
contact affiliation	Vall Hebron Institute of Oncology
contact email	fcanals@vhio.net
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2023/01/PXD032359

PRIDE project URI

• PRIDE
  1. PXD032359
     1. Label: PRIDE project
     2. Name: Circulating SOD2 is a Response Biomarker for Neoadjuvant Therapy in Breast Cancer